Gilead’s Kite data at EHA 2024 demonstrate ‘positive’ patient outcomes

Kite, a Gilead Company, announced 12 abstracts from its Chimeric Antigen Receptor T-cell therapy portfolio at the upcoming 2024 European Hematology Association annual Congress, June 13-16, Madrid, Spain. Four presentations will highlight real-world experience with Yescarta, including manufacturing experience for patients with relapsed/refractory large B-cell lymphoma in second-line versus third-line treatment and beyond. The real-world manufacturing analysis investigated potential benefits of administering Yescarta in earlier lines of therapy by assessing manufacturing success rate and product characteristics. Analyses exploring outpatient administration of Yescarta in R/R LBCL includes preliminary results of the Phase 2 ZUMA-24 study to evaluate the safety and efficacy of Yescarta outpatient administration compared to previous in-hospital clinical trials and real-world evidence. A real-world analysis on the use of Yescarta and Tecartu assess safety trends and hospitalization rates following treatment to further understand the feasibility of CAR T-cell therapy administration in the outpatient setting. “Whether it’s continuing to evolve our industry-leading manufacturing capabilities or looking at different ways patients can obtain CAR T-cell therapy, such as in the outpatient setting, our goal is to improve patient outcomes and experience with our therapies,” said Ibrahim Elhoussieny, Vice President, Medical Affairs, Kite. “These data will reflect our progress in helping CAR T reach more people with complex and hard-to-treat blood cancers.”